GRI 0.97 GRI Bio, Inc.
| Range: | 0.302-134.68 | Vol Avg: | 1318829 | Last Div: | 0 | Changes: | 0.09 |
| Beta: | -1.8 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Feb 10 2021 | Empoloyees: | 4 | ||
| CUSIP: | CIK: | 0000084112 | ISIN: | US3622AW2059 | Country: | US | |
| CEO: | Ms. Cristina Gil White | Website: | https://www.gribio.com | ||||
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Stock Details
Positive 0.18
GRI Bio Announces Exercise of Warrants
LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or ...
globenewswire.com·Mon Oct 21 2024
Neutral 0.00
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF...
globenewswire.com·Wed Oct 16 2024
Positive 0.52
UK residential rent rises are slowing but Grainger says demand remains strong
Grainger Plc (LSE:GRI) reported slower rental growth for recent months and said it expects...
proactiveinvestors.co.uk·Mon Oct 07 2024
Positive 0.17
GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment
Live video webcast on Wednesday, October 2 nd at 12:00 PM ET LA JOLLA, CA, Sept. 25, 2024 ...
globenewswire.com·Wed Sep 25 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow